TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05152160

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cell Therapy
Description: Umbilical Cord Mesenchymal Stem Cell Therapy
Study: NCT05486338

Intervention type: DEVICE
Group type: OTHER
Intervention: Hybrid Argon Plasma Coagulation (HAPC)
Description: Gastric mucosal ablation is an endoscopic procedure which uses argonplasma coagulation in combination with submucosal injection to achieve selective ablation to the gastric mucosa and preventing thermal damage to the muscle layer.
Study: NCT05002777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rilzabrutinib
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study: NCT04815434

Intervention type: OTHER
Intervention: Interview
Description: Interviews will be conducted.
Study: NCT05413733

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital care pathway
Description: Sessions of the digital neuropsychological program:~1. Subjective functional ability and goals~2. Fatigue after ABI~3. Attention and concentration~4. Memory~5. Memory strategies~6. Working memory and executive functions~7. Emotional reactions~8. Summary and future goals

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual
Description: The standard care of patients with ABI including all necessary outpatient rehabilitation visits. Neuropsychological visits may include a short period of psychoeducation with a clinical neuropsychologist.
Study: NCT05452434

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mirabegron
Description: mirabegron 50mg QD for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: mirabegron 50mg QD for 12 weeks.
Study: NCT06539676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nighttime Aligners
Description: Nighttime aligners worn 10-12 hours per day or night during 2-8 months
Study: NCT04932460

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CEUS
Description: CEUS is performed before neoadjuvant treatment and surgery to evaluate the status of axillary lymph node and locate the sentinel lymph node.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blue dye
Description: Before operation, blue dye is injected for sentinel lymph node mapping.
Study: NCT05095038

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Appethyl®
Description: Spinach extract, capsules, 5g/day, 26 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pea protein, capsules, 5g/day, 26 weeks.
Study: NCT05985395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEART Camp Connect
Description: Once eligible and enrolled, participants will complete 150 minutes of moderate-intensity exercise a week with help of a virtual exercise coach.
Study: NCT05490953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Patients will be treated pentoxifylline during the first two chemotherapy cycles of their respective treatment.
Study: NCT05100901

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MAG oil oral nutritional supplement (ONS)
Description: The study product is suitable for use as an oral nutritional supplement (ONS).The study product contains MAG oil, hydrolyzed whey protein, simple carbohydrates, vitamins and minerals.
Study: NCT06033144

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of Tapia's Syndrome
Description: The diagnostic includes :~* Lingual clinical examination~* Nasofibroscopy~* Ultrasonography

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of Tapia's Syndrome
Description: The diagnostic includes :~* Lingual clinical examination~* Nasofibroscopy~* Ultrasonography
Study: NCT05309486

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online and Face-to-face Pilates trainings
Description: Key elements of Pilates, including breathing, focusing, rib cage position, shoulder position, and head and neck positions, will be taught in both groups on the first day. Individuals will be asked to maintain the smoothness of these critical elements throughout the exercises. Different imagery techniques will be used in the exercises, and the exercises will be combined with breathing exercises. The intensity of the exercises will be increased by using different positions and elastic bands (Theraband Elastic Band Hygienic Corporation, Akron, Ohio). Band Resistances will be increased in biweekly periods. Stretching and posture exercises will be used during the cool-down period. The subjects in pilates group will be informed about the side effects such as shortness of breath, dizziness, headache, and muscle pain. Participants will be asked to stop the exercise in case of any side effects.
Study: NCT05490953

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be treated with placebo during the first two chemotherapy cycles of their respective treatment.
Study: NCT06539676

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Daytime Aligners
Description: Daytime aligners worn 20-22 hours per day or night during 2-8 months
Study: NCT05832164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Description: * Adherence to a Mediterranean diet.~* Progressive aerobic and anaerobic exercise program.~* Review of polypharmacy~* Group socialization activities
Study: NCT06373081

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19-CD3E-CAR-T cells
Description: The injection of anti-CD19-CD3E chimeric antigen receptor T (CAR-T) cells, referred to as anti-CD19-CD3E-CAR-T cells. The anti-CD19-CD3E-CAR protein is composed of a murine-derived CD19 single-chain variable fragment (scFv) FMC63, CD28 hinge and transmembrane regions, the intracellular domain of CD3E, the intracellular domain of CD28, and the intracellular domain of CD3ζ, all linked in sequence.
Study: NCT06157580

Intervention type: DRUG
Group type: OTHER
Intervention: Compound 21
Description: differences in vasodilation to compound 21 in the skin between groups

Intervention type: DRUG
Group type: OTHER
Intervention: Compound 21
Description: differences in vasodilation to compound 21 in the skin between groups

Intervention type: DRUG
Group type: OTHER
Intervention: Angiotensin II
Description: differences in vasoconstriction to angiotensin II in the skin between groups

Intervention type: DRUG
Group type: OTHER
Intervention: Angiotensin II
Description: differences in vasoconstriction to angiotensin II in the skin between groups
Study: NCT04929262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supporting Anxious Youth: Strategies for Caregivers
Description: The outreach presentation will last 75 minutes with an additional 15 minutes for caregiver questions. The presentations will occur in the evening via Zoom. The presentation will include information about identifying anxiety disorders, strategies for caregivers to help their youth with anxiety, evidence-based practices to treat youth anxiety, and strategies for finding a therapist who uses cognitive behavior therapy with exposures. The text on the presentations is written at a 5.3 grade reading level. Presentations will incorporate stigma reduction strategies, such as education to dispel myths, and behavioral decision-making tools to elicit hope, empowerment, and motivation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supporting Anxious Youth: Strategies for Caregivers
Description: The outreach presentation will last 75 minutes with an additional 15 minutes for caregiver questions. The presentations will occur in the evening via Zoom. The presentation will include information about identifying anxiety disorders, strategies for caregivers to help their youth with anxiety, evidence-based practices to treat youth anxiety, and strategies for finding a therapist who uses cognitive behavior therapy with exposures. The text on the presentations is written at a 5.3 grade reading level. Presentations will incorporate stigma reduction strategies, such as education to dispel myths, and behavioral decision-making tools to elicit hope, empowerment, and motivation.
Study: NCT05961592

Intervention type: DRUG
Group type: OTHER
Intervention: R-2487
Description: Probiotic
Study: NCT06027242

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: oral glutamine
Description: 10 g glutamine +5 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin
Study: NCT05309486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online and Face-to-face Pilates trainings
Description: Key elements of Pilates, including breathing, focusing, rib cage position, shoulder position, and head and neck positions, will be taught in both groups on the first day. Individuals will be asked to maintain the smoothness of these critical elements throughout the exercises. Different imagery techniques will be used in the exercises, and the exercises will be combined with breathing exercises. The intensity of the exercises will be increased by using different positions and elastic bands (Theraband Elastic Band Hygienic Corporation, Akron, Ohio). Band Resistances will be increased in biweekly periods. Stretching and posture exercises will be used during the cool-down period. The subjects in pilates group will be informed about the side effects such as shortness of breath, dizziness, headache, and muscle pain. Participants will be asked to stop the exercise in case of any side effects.
Study: NCT04635111

Intervention type: DRUG
Intervention: TURALIO™
Description: This is a non-interventional, observational study to evaluate long-term risk of hepatic failure associated with TURALIO™ (pexidartinib) treatment. No study medication will be provided to the participants.
Study: NCT06094062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: App-based treatment support
Description: The intervention includes a smartphone app that patients will download on their smartphones. Medication intake, symptom course and well-being will be tracked over treatment duration. If symptoms worsen, the pharmacist will contact the patients and counsel them based on their adherence and well-being data. Patients who still have symptoms after the 30 days of treatment will receive a final counseling by the pharmacy, and if necessary will be forwarded to the treating physician.
Study: NCT05304390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Receive patient navigation intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Receive an intervention for smoking cessation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carbon Monoxide Measurement
Description: Undergo carbon monoxide measurement
Study: NCT05824338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia for lumbar surgery: ropivacaine
Description: The anesthesiologist will administer 4 mL of ropivacaine 0.5% plus fentanyl 15 mcg intrathecally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia for lumbar surgery: bupivacaine
Description: The anesthesiologist will administer 3 mL of bupivacaine 0.5% plus fentanyl 15 mcg intrathecally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia for lumbar surgery
Description: Patient will be intubated and ventilated under general anesthesia.
Study: NCT06337110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF28996
Description: Oral solution containing radiolabelled \[14C\]-Lu AF28996.
Study: NCT06114472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aromatherapy blend containing Lavender
Description: hree drops of aromatherapy blend containing Lavender essence 10% were poured on cotton in cast containers, and the patient was asked to inhale it for 5 minutes from a distance of 10 cm
Study: NCT05306600

Intervention type: DIAGNOSTIC_TEST
Intervention: whole exome and whole genome sequencing analysis
Description: Somatic and germline whole exome sequencing will be analyzed for prostate and HER2-positive breast cancer~Somatic whole exome and germline whole genome sequencing will be analyzed for triple-negative breast cancer

Intervention type: DIAGNOSTIC_TEST
Intervention: whole exome and whole genome sequencing analysis
Description: Somatic and germline whole exome sequencing will be analyzed for prostate and HER2-positive breast cancer~Somatic whole exome and germline whole genome sequencing will be analyzed for triple-negative breast cancer
Study: NCT06209359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ammonium Chloride
Description: Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.
Study: NCT05487586

Intervention type: DRUG
Intervention: ceftazidime avibactam group
Description: Non-Interventional Study
Study: NCT05284058

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance Imaging (MRI)
Description: Patients will undergo 2 MRI exams: 1 MRI before surgical intervention (maximum 21 days before) and 1 MRI three months after surgery (+/- 14 days), with intravenous administration of gadolinium.
Study: NCT05823987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H101
Description: a modified human recombinant type 5 adenovirus with genetic modifications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: a PD-1 immune check inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib capsules
Study: NCT05608967

Intervention type: DEVICE
Intervention: PREHapp
Description: Prehabilitation programme through the PREHapp platform
Study: NCT06165679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocaine
Description: The patients will receive a single injection of spinal anesthesia using prilocaine plus fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: The patients will receive a single injection of spinal anesthesia using Bupivacaine plus fentanyl
Study: NCT05800821

Intervention type: PROCEDURE
Intervention: Carotid revascularization
Description: Carotid revascularization
Study: NCT04733495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Receive group-based behavioral counseling
Study: NCT04733495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Counseling and Surveillance
Description: Receive dietary counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT05290740

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine 5 mcg
Description: norepinephrine bolus of 5 mcg for treatment of sever postspinal hypotension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine 10 mcg
Description: norepinephrine bolus of 10 mcg for treatment of sever postspinal hypotension
Study: NCT06569082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CD34+ Selected Donor Cell Boost
Description: The CliniMACS CD34 Reagent System is used to separate CD34 cells from the remaining stem cell product, using a peripheral blood stem cell sample provided by the original donor. These CD34 cells are then infused into the recipient following selection with the intent to restore function of the blood forming cells.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Stem Cell Infusion
Description: The selected CD34 cells separated by the CliniMACS CD34 Reagent System are infused into the recipient.
Study: NCT05933577

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V940
Description: IM injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: IM injection
Study: NCT05672576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod
Description: Cenerimod will be supplied as film-coated tablets at the dose of 4 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.
Study: NCT06392100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention
Description: Mindfulness-based stress reduction interventions include: breathing awareness, loving-kindness meditation, body scan, walking meditation, sitting body awareness, eating meditation, and deep breathing exercises.
Study: NCT06309719

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Periodontal Access Flap (AF) + Combined Formulation of Hyaluronic acid and Polydeoxyribonucleotides (PNHA)
Description: A conservative access flap will be performed such as simplified papilla preservation flap (SPPF). A PNHA gel will be placed on the root surfaces and supra-bony defects, followed by a tension-free primary closure of the interdental papillae and of the mucoperiosteal flaps by means of 5-0 suture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal Access Flap (AF)
Description: A conservative access flap will be performed such as simplified papilla preservation flap (SPPF). No gel will be placed before suturing the flap by tension-free primary closure of the interdental papillae and of the mucoperiosteal flaps by means of 5-0 suture
Study: NCT05094596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standart treatment group
Description: Group 1 (n=60) received standard treatment in accordance with our national COVID-19 diagnosis and treatment guide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standart treatment group
Description: Group 1 (n=60) received standard treatment in accordance with our national COVID-19 diagnosis and treatment guide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standart treatment group
Description: Group 1 (n=60) received standard treatment in accordance with our national COVID-19 diagnosis and treatment guide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast sodium 10 mg treatment
Description: Group 2 (n=60) received 10 mg/day oral montelukast in addition to standard treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast sodium 20 mg treatment
Description: Group 3 (n=60) were given 20 mg/day oral montelukast in addition to standard treatment.
Study: NCT05787392

Intervention type: BEHAVIORAL
Intervention: Chamas cha MamaToto program
Description: Chamas is a community health volunteer (CHV)-led group programme that engages women during pregnancy and the first 1000 days of their child's life. The strategy focuses on promoting maternal, newborn, and child health (MNCH) by providing health education, peer support, and opportunities to access financial capital, all while addressing inequities that perpetuate poor outcomes.

Intervention type: BEHAVIORAL
Intervention: Chamas cha MamaToto program
Description: Chamas is a community health volunteer (CHV)-led group programme that engages women during pregnancy and the first 1000 days of their child's life. The strategy focuses on promoting maternal, newborn, and child health (MNCH) by providing health education, peer support, and opportunities to access financial capital, all while addressing inequities that perpetuate poor outcomes.
Study: NCT05974943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Problem Solving And Decision Making Education
Description: The Problem-Solving and Decision-Making Training Program, which was based on developing problem-solving and decision-making skills of nurse managers in the experimental group (n=30), was prepared. 2 faculty members and the researcher organized the training program consisting of four modules and 16 hours.~In the content of the Training Program; the definition of the concept of problem-solving and decision-making, the process of problem-solving and decision-making and decision-making models, the impact of decision-making on employee, patient and organizational outcomes, and the importance of managers' roles in decision-making, the importance of the role of nurse managers in decision making, the impact of managerial decisions on patient care outcomes, the impact of managerial decisions on nurse outcomes, the impact of administrative decisions on organizational results/performance, problem-solving, and decision-making techniques and case studies.
Study: NCT05478122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trachospray for awake videolaryngoscopy
Description: Subjects will be asked to inhale 4 ml lidocaine 4% via the Trachospray device
Study: NCT06107920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Description: Diverting stoma- neoadjuvant chemotherapy - colectomy - +/- adjuvant chemotherapy
Study: NCT05552547

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home Blood Pressure Machine
Description: Participants will be asked to measure blood pressure twice daily for three days in a row at home.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 24-Hour Blood Pressure Machine
Description: Participants will be asked to wear the machine for 24 hours.
Study: NCT05060185

Intervention type: DEVICE
Group type: OTHER
Intervention: the Flow Diverter
Description: Those who meet the inclusion criteria but do not meet the exclusion criteria will be enrolled through the electronic central registration system. The investigator log in to the central registration system, fill in the subject information and submit it who enroll in the study. The investigator complete the surgery and conduct relevant evaluation according to the protocol.
Study: NCT06253975

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adipose tissue derived extracellular vesicles (AT-EVs)
Description: Extracellular vesicles from patient's adipose tissue together with HA
Study: NCT06582628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide capsule
Description: Enzalutamide capsules 160 mg orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide capsule and Talazoparib capsule
Description: Enzalutamide capsules 160 mg plus talazoparib capsules 0.5 mg, both orally daily